Morganella morganii: Difference between revisions
From IDWiki
Morganella morganii
Content deleted Content added
No edit summary |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 9: | Line 9: | ||
== Clinical Manifestations == |
== Clinical Manifestations == |
||
* 30% are polymicrobial[[CiteRef::lin2014cl]] |
* 30% are polymicrobial[[CiteRef::lin2014cl]][[CiteRef::papp-wallace2022mo]] |
||
* Sources include urinary tract, hepatobiliary tract, skin and soft tissue (including post-operative infection), and bacteremia without focus[[CiteRef::lin2014cl]][[CiteRef::erlanger2019cl]] |
* Sources include urinary tract, hepatobiliary tract, skin and soft tissue (including post-operative infection), and bacteremia without focus[[CiteRef::lin2014cl]][[CiteRef::erlanger2019cl]][[CiteRef::papp-wallace2022mo]] |
||
* Occasional cases of CLABSI and respiratory infection[[CiteRef::erlanger2019cl]] |
* Occasional cases of CLABSI and respiratory infection[[CiteRef::erlanger2019cl]][[CiteRef::papp-wallace2022mo]] |
||
* Case reports of endocarditis[[CiteRef::li2023en]] |
|||
== Management == |
== Management == |
||
Latest revision as of 15:33, 2 January 2026
Background
Microbiology
- Gram-negative bacillus
Clinical Manifestations
- 30% are polymicrobial12
- Sources include urinary tract, hepatobiliary tract, skin and soft tissue (including post-operative infection), and bacteremia without focus132
- Occasional cases of CLABSI and respiratory infection32
- Case reports of endocarditis4
Management
- Intrinsically resistant to ampicillin, amoxicillin-clavulanic acid, first-generation cephalosporins, tigecycline (but not tetracyclines), nitrofurantoin, colistin
References
- a b T.-Y. Lin, M.-C. Chan, Y.-S. Yang, Y. Lee, K.-M. Yeh, J.-C. Lin, F.-Y. Chang. Clinical manifestations and prognostic factors of Morganella morganii bacteremia. European Journal of Clinical Microbiology & Infectious Diseases. 2014;34(2):231-236. doi:10.1007/s10096-014-2222-8.
- a b c Kevin B. Laupland, David L. Paterson, Felicity Edwards, Adam G. Stewart, Patrick N. A. Harris. Krisztina M. Papp-Wallace. Morganella morganii, an Emerging Cause of Bloodstream Infections. Microbiology Spectrum. 2022;10(3). doi:10.1128/spectrum.00569-22.
- a b David Erlanger, Marc Victor Assous, Yonit Wiener-Well, Amos Moshe Yinnon, Eli Ben-Chetrit. Clinical manifestations, risk factors and prognosis of patients with Morganella morganii sepsis. Journal of Microbiology, Immunology and Infection. 2019;52(3):443-448. doi:10.1016/j.jmii.2017.08.010.
- ^ Chaoran Li, Hui Wang, Jinzhou Zhang, Zhen Wang, Yuxiu Wei, Yunkui Zhu. Endocarditis induced by M. morganii in an immunocompetent patient without underlying valvular abnormalities. Heliyon. 2023;9(6):e17069. doi:10.1016/j.heliyon.2023.e17069.
